MedTrace Logo

"Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally" Study

NCT02960828 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2019-09-19

No results posted yet for this study

Summary

This study aims to validate the efficacy and safety of subthreshold laser photocoagulation on high-risk macular drusen in early age-related macular degeneration which has a high risk of conversion to exudative AMD.

Conditions

  • Age-Related Macular Degeneration
  • Retinal Drusen

Interventions

PROCEDURE

Subthreshold Laser Photocoagulation

Selective Subthreshold Laser Photocoagulation is applied to the periphery of high-risk macular drusen

DRUG

intravitreal Anti-VEGF injection

To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.

DEVICE

Subthreshold Laser

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Principal Investigators

  • Kyu Hyung Park, M.D., Ph.D. · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2020-05-31
Completion
2020-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02960828 on ClinicalTrials.gov